[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Centre Hospitalier Universitaire de Liege\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":503},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,19,0,[8,44,72,94,123,151,178,200,222,257,289,312,330,355,381,410,432,461,480],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100644445","digital-monitoring-of-upper-limb-function-in-non-ambulant-dmd-100644445",false,"NCT07664124","Digital Monitoring of Upper Limb Function in Non-Ambulant DMD","Feasibility, Reliability, Clinical Validity and Sensitivity of Digital Outcomes to Monitor Upper Limb Function in Non-ambulant Patients With Genetically Confirmed Duchenne Muscular Dystrophy (DMD)","Acti-nRoll","Inclusion Criteria:\n\n* Patient with genetically confirmed Duchenne Muscular Dystrophy (DMD).\n* Non-ambulant at the time of inclusion (not able to walk 10m without external aid).\n* A legal guardian willing and able to provide written informed consent for participation in the study if \\\u003C 18 years old.\n\nExclusion Criteria:\n\n* Any acute or chronic condition that, in the opinion of the investigator, may significantly interfere with the assessments and\u002For motor function progression.\n* Participation in an interventional clinical trial.\n* No access to internet connection or alternatively no capacity to come on-site to bring the Syde every 6 months after the recording periods for data retrieval by Liège team\n* Scoliosis surgery within the previous 6 months or planned within the next year","MALE",{"count":19,"type":20},50,"ESTIMATED","INTERVENTIONAL",[23],"NA","Duchenne Muscular Dystrophy (DMD) is a rare genetic disorder caused by the absence of dystrophin, leading to progressive muscle degeneration. Symptoms typically begin in early childhood and result in loss of ambulation by early adolescence, followed by cardiorespiratory complications. Although early treatment, including corticosteroids and emerging therapies, can slow disease progression, sensitive tools to monitor functional decline-particularly in non-ambulant patients-remain limited.\n\nCurrent assessments rely primarily on clinical scales and hospital-based evaluations, which may not detect subtle changes or reflect real-life function. Digital outcome measures derived from wearable sensors offer a promising approach for continuous, objective monitoring in daily life. This study aims to evaluate the feasibility, reliability, clinical validity, and sensitivity of digital measures to assess upper limb function in non-ambulant patients with genetically confirmed DMD. The Syde device, previously validated in ambulant DMD patients, will be investigated for its applicability in this population.",[26],"Duchenne Muscular Dystrophy (DMD)",[28,29,30],"Non-ambulant","digital endpoint","upper limb","NOT_YET_RECRUITING","2026-06-18",{"date":34,"type":35},"2026-06-23","ACTUAL",{"date":37,"type":20},"2026-07-30",{"date":39,"type":20},"2030-04-30",{"name":41,"class":42},"Centre Hospitalier Universitaire de Liege","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":52,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":43},"100603437","gait-analysis-parameter-and-upper-limb-evaluation-in-control-participants-100603437","NCT07136506","Gait Analysis Parameter and Upper Limb Evaluation in Control Participants","ActiControl","Inclusion Criteria:\n\n* Male and female of different age groups\n* Signed informed consent form by participant him\u002Fherself or, in case of patients \\\u003C18 years old, signed informed consent form by patient's parents or legal guardians\n* Able to ambulate (minimum 10 meters without help)\n* Participant willing and able to comply with all study procedures\n\nExclusion Criteria:\n\n* Patients who have undergone a surgical procedure or who have experienced recent trauma (within fewer than 6 months) affecting the upper or lower limbs\n* Elite athletes (at the national level)\n* Pregnant women\n* A chronic or acute muscular, neurological, infectious, or inflammatory pathology within the 3-week period immediately prior to inclusion\n* An orthopedic, neuromuscular, or neurological pathology that affects the quality of the participant's walking gait\n* No access to unlimited internet connection or alternatively no capacity to come on-site to upload Syde data",true,"ALL","18 Years",{"count":55,"type":20},200,[23],"The ActiControl study is a monocentric, academic, and fully remote observational study designed to build a normative, longitudinal dataset using the Syde® wearable device. The study will enroll 200 healthy volunteers across all age groups, genders, and backgrounds. Participants will be remotely recruited and followed over two years, wearing the Syde® device for 3-week periods every 6 months. All study visits, including consent, data collection, and follow-up, are conducted remotely via phone or video conferencing. The primary objectives are to collect reference data on gait and movement patterns and to assess adherence and acceptability of the device. Secondary objectives include evaluating the reliability of digital endpoints and the influence of demographic and lifestyle factors on these measures.",[59],"Healthy Participants",[59,61,62],"Healthy Volunteers","Healthy Adults","RECRUITING","2026-05-18",{"date":66,"type":35},"2026-05-19",{"date":68,"type":35},"2025-09-24",{"date":70,"type":20},"2028-12",{"name":41,"class":42},{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":52,"minAge":4,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":21,"phases":82,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":43},"100608444","natural-history-study-for-patients-with-nemaline-myopathy-in-belgium-100608444","NCT07201636","Natural History Study for Patients With Nemaline Myopathy in Belgium","A Monocentre, Prospective, Longitudinal and Observational Natural History Study for Patients With Nemaline Myopathy","Acti-Nemaline","Inclusion Criteria:\n\n* Male or Female\n* Any age\n* Patient and\u002For parent or legal guardian must be willing and have the ability to provide written informed consent for participation in the study.\n* Diagnosis of NM which in most cases includes having a disease-causing variant\u002Fs in one of the known NM causative genes and a consistent clinical phenotype.\n\nExclusion Criteria:\n\n* Any confirmed chronic or acute condition or disease affecting any system(s), which could interfere with the results of the study and\u002For the compliance with the study procedures. This will be subject to the clinical judgement of the Coordinating Investigator (CI) and\u002For the Principal Investigator (PI).\n* Clinically significant medical finding on the physical examination other than NM that, in the judgment of the Investigator, will make the patient unsuitable for participation in, and\u002For completion of the study procedures.\n* Participants of ongoing (interventional) clinical trials that assess the efficacy of potential treatments will be excluded as assessments need to be done on the basis that represent the natural progression of NM.\n* Safety concerns. This includes anything that might put the participant and\u002For their Parent(s) or Guardian(s) at risk through participating in the study potentially including but not limited to: Safeguarding concerns, Social Issues and Health issues.\n* Ongoing pregnancy (for participants becoming pregnant during the trial, some assessments may be cancelled or postponed. This will be subject to the clinical judgement of the Coordinating Investigator and\u002For the Principal Investigator)",{"count":81,"type":20},10,[23],"This is a prospective, longitudinal, observational study designed to characterize the natural history of Nemaline Myopathy (NM), a rare congenital neuromuscular disorder. The study will follow up to 10 participants of any age with genetically confirmed NM over a period of three years. Data will be collected during routine annual hospital visits and include clinical, motor, respiratory, and quality-of-life assessments. The goal is to improve clinical trial readiness by identifying disease-specific outcome measures and potential biomarkers.",[85],"Nemaline Myopathy","2026-03-24",{"date":88,"type":35},"2026-03-25",{"date":90,"type":20},"2026-08",{"date":92,"type":20},"2029-08",{"name":41,"class":42},{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":51,"sex":52,"minAge":53,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":21,"phases":104,"briefSummary":105,"conditions":106,"keywords":108,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":122},"100627785","selective-versus-contiguous-connective-tissue-grafts-in-the-modified-tunnel-technique-100627785","NCT07453147","Selective Versus Contiguous Connective Tissue Grafts in the Modified Tunnel Technique","Evaluation of the Modified Coronally Advanced Tunnel Technique Associated With a Selective\u002FSegmented Versus Contiguous Submerged Connective Tissue Graft for the Treatment of Multiple Gingival Recessions: Randomised Controlled Clinical Trial","MCATTs","Inclusion Criteria:\n\n* ASA I or ASA II\n* Good periodontal health\n* Able to undergo oral surgery\n* Must be 18 years old and older\n* No smoking\n* At least two teeth in the same sector in the maxilla and the right and left mandible (except in the mandibular incisive sector), of which at least 2 are contiguous, with vestibular gingival recessions of type RT 1 of 1-5mm (Cairo et al. 2011)\n* An identifiable or restorable cemento-enamel junction (CEJ), with or without the presence of a non-carious cervical lesion (Pini-Prato et al. 2010)\n* Plaque index (O'Leary 1972) and bleeding index (Ainamo et al. 1975) scores of less than 20%\n* Able to give informed consent and have signed the consent forms\n\nExclusion Criteria:\n\n* Teeth showing recession associated with a carious lesion, restoration or cervical prosthesis involving CEJ\n* Teeth with recession depth \\>5mm\n* Molars with recessions will be treated but will not be taken into account for the measurements\n* Teeth with recession that have already undergone periodontal surgery\n* Presence of severe tooth malposition, rotation or significant version of the tooth\n* Smoker and ex-smoker\n* Patient suffering from a disease affecting the periodontium\n* Patient with clinical signs of active periodontitis\n* Known pregnancy in progress or breastfeeding\n* Contraindication to surgery\n* Conditions or circumstances which would prevent completion of study participation or interfere with analysis of study results, such as history of no-compliance or unreliability\n* Patients deprived of their liberty or under legal protection",{"count":103,"type":20},32,[23],"The goal of this study is to evaluate how effective a gum grafting procedure is in treating gum recession that affects several teeth. Gum recession happens when the gum tissue pulls away from the tooth, exposing the roots. The study will look at how the treatment improves gum health, appearance, and function.\n\nA total of 32 patients will take part in the study. All patients will be treated with a modified coronally advanced tunnel. For half of them of contiguous graft will be used, for the other half a segmented graft.\n\nData collected will include medical history, dental and aesthetic information, clinical measurements, and a digital scan of the mouth.\n\nThe study will include the following steps:\n\nBefore the procedure: You will have a clinical and X-ray examination to determine how much your gums have receded. A digital impression of your teeth will also be taken.\n\nSurgical procedure: You will receive a gum graft to cover the exposed roots. This involves moving gum tissue, often taken from the roof of your mouth, to the affected areas.\n\nAfter the procedure: You will have several follow-up visits over a few months to check your healing and the results of the treatment.\n\nStudy timeline:\n\nThe surgery will be done once. Follow-up visits will take place 1, 3, 6, and 12 months after the surgery. The total duration of the study is about 12 months.",[107],"Gum Recession",[109,110,111,112,113],"Gum recession","Recession treatment","Tunnel technique","Connective tissue graft","Gingival recession","2026-03-03",{"date":116,"type":35},"2026-03-05",{"date":118,"type":35},"2025-09-01",{"date":120,"type":20},"2028-09-01",{"name":41,"class":42},2,{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":52,"minAge":131,"maxAge":132,"enrollmentInfo":133,"targetDuration":4,"studyType":21,"phases":135,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":4},"100624340","early-diagnosis-and-cardiovascular-risk-stratification-in-children-exposed-to-cancer-therapies-100624340","NCT07408362","Early Diagnosis and Cardiovascular Risk Stratification in Children Exposed to Cancer Therapies","How to Improve Early Diagnosis and Cardiovascular Risk Stratification in Children Exposed to Chemotherapy and\u002For Thoracic Radiotherapy? Multimodal Cardiological Evaluation and Biomarkers.","CTRCT-pedia","Inclusion Criteria:\n\n* History of chemotherapy and\u002For radiotherapy for an oncological condition or bone marrow transplantation (hematologic disease) after 01\u002F01\u002F2016.\n* Age \\\u003C 18 years at the time of treatment.\n* Cancer remission for more than one year.\n* Voluntary participation following comprehensive informed consent.\n* Signed informed consent from the patient (≥ 18 years) or from parents\u002Flegal guardians, with signed assent for minors aged 8 to 17.\n\nExclusion Criteria:\n\n* Active disease recurrence or relapse.\n* Current administration of antineoplastic therapy.\n* Withdrawal of consent or refusal to participate by the patient or their legal representatives.","2 Years","25 Years",{"count":134,"type":20},100,[23],"The goal of this prospective interventional study is to improve the detection of subclinical chronic Cancer Therapy-Related Cardiovascular Toxicity (CTRCT) and evaluate the added value of advanced cardioechography, ergospirometry, and specific biomarkers in pediatric cancer survivors (aged 2 to 25) who received potentially cardiotoxic treatments (chemotherapy\u002Fthoracic radiotherapy). The main questions it aims to answer are:\n\n* Can advanced echocardiography (including strain and myocardial work), ECG, and ergospirometry effectively diagnose earlier subclinical cardiac impairment in this population?\n* What is the prevalence of cardiovascular risk factors (including physical activity levels and biological markers like proBNP\u002Ftroponins)\n* Can new genetic or biological markers be identified to help optimizing the detection of CTRCT?\n\nAt time of follow-up, if they agree, participants will:\n\n* Complete validated questionnaires regarding quality of life, physical activity, and sedentary behavior.\n* Undergo a cardiopulmonary exercise test (ergospirometry) for those aged over 8 years.\n* Wear an accelerometer (ActiGraph GT3X) for 7 consecutive days to monitor physical activity.\n* Provide an additional blood sample during routine follow-up for the creation of a biobank dedicated to analyzing markers of senescence, fibrosis, apoptosis, and genetic polymorphisms.",[138,139,140,141,142],"Cancer Therapy-related Cardiovascular Toxicity","Childhood Cancer","Chemotherapeutic Toxicity","Radiotherapy Side Effect","Cardiovascular Complication","2026-02-10",{"date":145,"type":35},"2026-02-13",{"date":147,"type":20},"2026-02-15",{"date":149,"type":20},"2033-12-31",{"name":41,"class":42},{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":52,"minAge":159,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":21,"phases":161,"briefSummary":162,"conditions":163,"keywords":165,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":43},"100614974","active-nbs-study-decentralised-monitoring-motor-development-in-children-with-duchenne-muscular-dystrophy-or-spinal-muscular-atrophy-identified-by-newborn-screening-100614974","NCT07286565","Active NBS Study: Decentralised Monitoring Motor Development in Children With Duchenne Muscular Dystrophy or Spinal Muscular Atrophy Identified by Newborn Screening","Active-NBS Liege - Monitoring the Motor Development of Children With Duchenne Muscular Dystrophy or Spinal Muscular Atrophy Identified Through Newborn Screening","Active-NBS BE","Inclusion Criteria:\n\nGenetically confirmed SMA and avalaible MSNA2 copy number:\n\n* Identified by newborn screening,\n* Identified by family screening, or incidental diagnosis in pre-symptomatic stage\n* Treated (or follow-up possible for patients with 4 SMN2 copies)\n\nGenetically confirmed DMD:\n\n* Identified by newborn screening,\n* Identified by family screening, or incidental diagnosis in pre-symptomatic stage\n* Age \\\u003C 4 years at inclusion\n\nLegal guardian able to provide informed consent\n\nExclusion Criteria:\n\n* Any acute or chronic condition that, in the investigator's opinion, significantly interferes with assessments and\u002For motor development.\n* Participation in a therapeutic trial.\n* Lack of internet connection.","4 Months",{"count":134,"type":20},[23],"The Active NBS Liege study is a monocentric, academic, fully remote, observational study designed to validate digital measures of motor development in children with spinal muscular atrophy (SMA) or Duchenne muscular dystrophy (DMD) identified through newborn screening, family testing, or incidental diagnosis. The study will enroll 100 children and follow them longitudinally for up to 30 months. Participants are remotely recruited, and all procedures, including consent, questionnaires, and follow-up visits, are conducted by phone or video conferencing without any hospital visits. Children will use age-appropriate wearable devices at home: MAIJU®, a sensorized garment for non-ambulant infants, and Syde®, an ankle-worn sensor for ambulant children. Data collection includes digital motor endpoints, clinical information, and quality of life (PedsQL). Primary objectives are to validate digital biomarkers of motor development, while secondary objectives include early identification of motor deficits, modeling motor trajectories, and quantifying genotype-related differences. Exploratory analyses will assess gait parameters such as stride velocity 95th centile (SV95C) and compare motor outcomes across genetic profiles and treatment exposure. Risks are minimal, limited to the use of non-invasive sensors with no known side effects.",[164,26],"Spinal Muscular Atrophy (SMA)",[166,167,168,169],"Remotely monitor","Syde","Accelerometry","Daily living","2025-12-12",{"date":172,"type":35},"2025-12-16",{"date":174,"type":35},"2025-12-01",{"date":176,"type":20},"2028-08",{"name":41,"class":42},{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":4,"eligibilityCriteria":184,"healthyVolunteers":51,"sex":52,"minAge":4,"maxAge":185,"enrollmentInfo":186,"targetDuration":4,"studyType":188,"phases":4,"briefSummary":189,"conditions":190,"keywords":191,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":196,"completionDateStruct":197,"leadSponsor":199,"locationsCount":43},"100605210","assessment-of-neurofilaments-levels-in-premature-newborns-study-of-their-early-development-100605210","NCT07159555","Assessment of Neurofilaments Levels in Premature Newborns: Study of Their Early Development","Neurofilaments Levels in Premature Newborns","Inclusion Criteria:\n\n* Gestational age between 34 and 37 weeks of amenorrhea.\n* Blood test scheduled for clinical reasons.\n* Signed parental consent.\n\nExclusion Criteria:\n\n* Known neurological disorders.\n* Severe congenital malformations.\n* Medical contraindication to blood sampling.","3 Weeks",{"count":187,"type":20},15,"OBSERVATIONAL","This is a prospective observational study aiming to establish reference values of neurofilaments in late preterm newborns (34-37 weeks of gestation) and to evaluate their early postnatal evolution.\n\nNeurofilaments are neuronal proteins released into the blood when nerve cells are damaged. They have emerged as promising biomarkers in neurodegenerative diseases, particularly in spinal muscular atrophy (SMA), where higher levels are associated with disease activity. However, very limited data exist on the normal dynamics of neurofilament levels in preterm infants.\n\nIn this study, up to 15 preterm newborns hospitalized in the neonatal unit will be enrolled (5 at 34 weeks, 5 at 35 weeks, 5 at 36 weeks of gestation). A maximum of 1 mL of additional blood will be collected only during routine clinically indicated blood draws, at birth, on day 2, and weekly until 37 weeks of gestation. Samples will be analyzed for neurofilament concentrations and compared across gestational ages, over time, and with existing data from term newborns and SMA patients.\n\nThe expected outcome is to generate normative data on neurofilament levels in late preterm infants, which will help interpret biomarker values in future studies and optimize early diagnosis and treatment strategies for neurodegenerative diseases such as SMA.",[59],[59,192,193],"Neurofilament","Premature infant","2025-12-11",{"date":170,"type":35},{"date":174,"type":35},{"date":198,"type":20},"2026-12-31",{"name":41,"class":42},{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":52,"minAge":53,"maxAge":4,"enrollmentInfo":207,"targetDuration":4,"studyType":21,"phases":209,"briefSummary":210,"conditions":211,"keywords":213,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":43},"100430271","continuous-measurement-of-activity-in-patients-with-muscle-pathology-and-in-control-subjects-actisla-part-100430271","NCT04882904","Continuous Measurement of Activity in Patients With Muscle Pathology and in Control Subjects. ActiSLA Part.","Continuous Measurement of Activity in Patients With Muscle Pathology and in Control Subjects","Inclusion Criteria:\n\n* Clinically defined or probable diagnosis of ALS according to El Escorial criteria revised with Awaji's electro-diagnostic algorithm.\n* Over 18 years old.\n* Signed informed consent\n* If patient on Riluzole, the dosage should be stable for 1 month and continued throughout the study period.\n\nExclusion Criteria:\n\n* Patients with excessive cognitive disorders, limiting the understanding of task or with apparent communication difficulties hindering data collection.\n* Any other previous or present pathology having an impact on motor function.\n* Recent surgery or trauma (less than 6 months) in the upper or lower limbs.\n* Prior neurological, endocrine, infectious, allergic, or chronic or acute inflammatory pathology in the three weeks preceding inclusion.\n* Patients participating in an interventional clinical trial.",{"count":208,"type":20},45,[23],"ActiSLA is a monocentric academic study. Patients with amyotrophic lateral sclerosis may be included on a voluntary basis. The investigators plan to include a group of approximately 20 patients with ALS.\n\nThe investigators have planned to assess patient every three months for a year. On each visit, participants will undergo a clinical examination with MRC sum score and Ashworth scores.\n\nThey will perform few tests ( 6-minutes walk test (6MWT), dynamometric measure, electromyography, Edinburgh Cognitive and Behavioural ALS Screen ) and will answer to some questionaires (dysphagia handicap scale, ALS-SFR-r).\n\nAfter each visit, participants will wear Actimyo for one month daily.",[212],"Amyotrophic Lateral Sclerosis",[214,168,169],"Actimyo",{"date":216,"type":35},"2025-12-05",{"date":218,"type":35},"2020-09-25",{"date":220,"type":20},"2026-12",{"name":41,"class":42},{"id":223,"slug":224,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":228,"eligibilityCriteria":229,"healthyVolunteers":11,"sex":17,"minAge":230,"maxAge":4,"enrollmentInfo":231,"targetDuration":4,"studyType":21,"phases":233,"briefSummary":235,"conditions":236,"keywords":240,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":122},"100604634","phase-2-stereotactic-focal-radiotherapy-as-an-alternative-treatment-to-active-surveillance-for-low-and-intermediate-risk-prostate-cancer-100604634","NCT07152067","Stereotactic Focal Radiotherapy as an Alternative Treatment to Active Surveillance for Low and Intermediate Risk Prostate Cancer","Stereotactic Focal Radiotherapy as an Alternative Treatment to Active Surveillance for Low and Intermediate Risk Prostate Cancer: a Multicentric Phase-II Randomized Trial","TOPPGUN-RS","* Inclusion Criteria (all the criteria must be fulfilled ) :\n\n  * a. Localized prostate adenocarcinoma CAPRA score ≤ 5. This lesion is considered the Index lesion\n  * b. Macroscopic tumor PIRADS score \\>4 on multiparametric MRI\n  * c. The biopsies must be pathologic in or in the direct vicinity (the same prostatic zone defined as a quarter volume of the prostate (PZ)) of the MRI pathologic nodule\n  * d. The absence of MRI pathologic criteria (PIRADS ≤3) in a Gleason score ≤ 6 (3+3)-ISUP Grade1 zone outside of the single Index lesion is considered clinically non-significant and does not preclude inclusion\n  * e. The lesion can be plurifocal in a same intent to treat PZ\n  * f. WHO Performance Status 0-1\n  * g. No major urinary symptoms with IPSS score ≤15 and urinary continence ICIQ score =0\n  * h. Patient is candidate for AS\n* Exclusion Criteria :\n\n  * a. Age at diagnosis \\\u003C 50 years\n  * b. Time between initial diagnostic biopsies and randomization \\> 4 months, or radiation therapy initiation \\> 6 months\n  * c. Cribriform or Intraductal histologic components\n  * d. Gleason Score ≥7 (3+4)-ISUP Grade 2 biopsy outside the intent to treat PZ\n  * e. Multicentric pathologic MRI (PIRADS ≥4) outside a same PZ\n  * f. Initial PSA \\> 20 ng\u002Fml\n  * g. Regional pathologic nodes or metastases\n  * h. Androgen-deprivation therapy\n  * i. Any cancer within the last 5 years except skin basocellular carcinoma or any uncontrolled cancer\n  * j. Urethral stenosis\n  * k. Recurrent prostatitis (at least 3 episodes within the last 3 years)\n  * l. Any inflammatory collagen disease.\n  * m. Contraindication to repeated prostatic biopsies or MRI","50 Years",{"count":232,"type":20},146,[234],"PHASE2","\\*Rationale : Active surveillance of prostate cancer helps to avoid the morbidity associated with curative radical prostatectomy \u002Fradiotherapy in patients with early stage disease. However, at 5 years and 15 years, respectively 35 % and nearly 50 % of patients require rescue interventional treatments. Numerous Phase II trials have reported using focal treatments (focused on the macroscopic tumor only while not involving the whole prostatic gland) in order to reduce the morbidity due to recurrence as well as the high anxiety rates under observation only. Stereotactic radiotherapy (highly focused radiotherapy technic to reduce the risk of side effects) is being proposed in the same way as it does not require any anaesthesia, as opposed to all the other focal methods. The purpose of this trial is to evaluate whether focal stereotactic radiotherapy treatments could reduce the rate of rescue treatments among patients eligible to an active surveillance program at first.\n\n* Major Inclusion Criteria :\n\n  * 1\\. Early stage prostate adenocarcinoma (CAPRA score ≤ 5)\n  * 2\\. No major urinary problems\n  * 3\\. Active Surveillance possible\n* Major Exclusion Criteria :\n\n  * 1\\. Age at diagnosis \\\u003C 50 years\n  * 8\\. Androgen-deprivation therapy\n  * 9\\. Any cancer within the last 5 years except skin basocellular carcinoma or any uncontrolled cancer\n* Trial : Phase II randomized trial comparing Stereotactic Radiation Therapy focused on the macroscopic tumor or Active Surveillance as the control arm.\n* Main objective : to compare the rescue treatment rates between the two arms",[237,238,239],"Macroscopic Tumor Visualized at MRI","Tumor Size Allowing Partial Prostate Treatment Volume","CAPRA SCORE ≤5",[241,242,243,244,245,246,247,248],"radiosurgery","focal treatment","early prostate cancer","active surveillance","Phase II randomized study","stereotactic radiotherapy","SBRT","quality of life","2025-08-28",{"date":251,"type":35},"2025-09-03",{"date":253,"type":20},"2025-09",{"date":255,"type":20},"2033-09-01",{"name":41,"class":42},{"id":258,"slug":259,"hasResults":11,"nctId":260,"briefTitle":261,"officialTitle":261,"acronym":262,"eligibilityCriteria":263,"healthyVolunteers":11,"sex":52,"minAge":53,"maxAge":4,"enrollmentInfo":264,"targetDuration":4,"studyType":21,"phases":266,"briefSummary":267,"conditions":268,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":43},"100603463","gait-analysis-parameter-and-upper-limb-evaluation-in-adult-patients-with-neurological-or-metabolic-pathology-100603463","NCT07136844","Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic Pathology","Acti-Adult","Inclusion Criteria:\n\n* Ambulant patients (i.e. able to walk 10 meters without assistance)\n* Confirmed diagnosis by the investigator based on current gold standard in his\u002Fher disease (genetic testing, clinical criteria, etc.)\n\n  * Myotonic dystrophy type 1 (DM1) and Charcot-Marie-Tooth (CMT) patients should present sensitive of motor signs on physical examination.\n  * Myasthenic patients should be seropositive, and Myasthenia Gravis Foundation of America (MGFA) class II to IV.\n  * Patient with morbid obesity (Body Mass Index\\> or = 35 at inclusion visit).\n* Signed informed consent form by patient him\u002Fherself and patient willing and able to comply with all study procedures.\n\nExclusion Criteria:\n\n* Non-ambulant patients\n* Patients with extreme cognitive disorders that limit their understanding of the exercises to be performed\n* Patients who have undergone a surgical procedure or who have experienced recent trauma (within fewer than 6 months) affecting the upper or lower limbs\n* A concomitant chronic or acute neurological, endocrine, infectious, allergic, or inflammatory pathology within the 3-week period immediately prior to inclusion\n* Patients who are participating in an interventional clinical trial\n* Pregnant or breastfeeding women",{"count":265,"type":20},300,[23],"The ActiLiège-Adult study is a prospective, longitudinal, observational study designed to collect natural history data on adult patients with neurological or metabolic diseases affecting movement. Conducted at the Centre de Référence Liégeois des Maladies Neuromusculaires in Liège, Belgium, the study will enroll 300 ambulant patients, including individuals with neuromuscular disorders and obesity. Using the Syde® wearable device, the study aims to continuously monitor motor function in real-life settings over a period of up to two years. The primary objective is to evaluate the utility of digital mobility outcomes, such as the 95th centile of stride velocity (SV95C), as reliable and objective endpoints for future clinical trials.",[269,270,271,272,273,274,275,276,277,278,279,280],"Neuromuscular Diseases","Obesity (Disorder)","Myotonic Dystrophy 1","Myasthenic Syndrome","Charcot Marie Tooth Disease (CMT)","Glycogen Storage Disease Type II Pompe Disease","Facio-Scapulo-Humeral Dystrophy","Myasthenia Gravis","Huntington Disease","Progressive Supranuclear Palsy (PSP)","Hereditary Spastic Paraplegia","Ataxia, Spinocerebellar","2025-08-14",{"date":283,"type":35},"2025-08-22",{"date":285,"type":35},"2024-03-29",{"date":287,"type":20},"2030-12",{"name":41,"class":42},{"id":290,"slug":291,"hasResults":11,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":295,"eligibilityCriteria":296,"healthyVolunteers":11,"sex":52,"minAge":4,"maxAge":4,"enrollmentInfo":297,"targetDuration":4,"studyType":188,"phases":4,"briefSummary":299,"conditions":300,"keywords":302,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":309,"leadSponsor":311,"locationsCount":43},"100533742","natural-history-study-for-patients-with-angelman-syndrome-100533742","NCT06229769","Natural History Study for Patients With Angelman Syndrome","A Monocentric, Prospective, Longitudinal and Observational Natural History Study for Patients With Angelman Syndrome in CHR Citadelle Liège : NatHis-Angelman","NatHisAngelman","Inclusion Criteria:\n\n* Genetically confirmed diagnosis of AS\n* 0-99 years\n* Male or Female\n* Participant's carer is willing to give IC\u002Fsign a \"record of consultation\" for participation in the study\n\nExclusion Criteria:\n\n* comorbidity that could potentially affect the results of the study coexists. This",{"count":298,"type":20},30,"This study is a 9-year natural history study for patients with Angelman syndrome in Belgium (a genetic neurodevelopmental disorder, affecting 500,000 individuals in the world). It includes a 3-year recruitment phase, a 5 year follow-up and a year to analyze the collected data. The investigators plan to include 30 patients with a semi-annual follow-up for 4 years.\n\nThe investigators will collect relevant retrospective and prospective data using age-standardized scales and questionnaires for functional motor assessments and global developmental assessment.",[301],"Angelman Syndrome",[303,168,169],"Actimyo°","2025-05-15",{"date":306,"type":35},"2025-05-20",{"date":308,"type":35},"2021-10-10",{"date":310,"type":20},"2028-01",{"name":41,"class":42},{"id":313,"slug":314,"hasResults":11,"nctId":315,"briefTitle":316,"officialTitle":316,"acronym":317,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":52,"minAge":53,"maxAge":4,"enrollmentInfo":318,"targetDuration":319,"studyType":188,"phases":4,"briefSummary":320,"conditions":321,"keywords":322,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":323,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":328,"locationsCount":329},"100533606","holter-of-movement-in-patients-with-amyotrophic-lateral-sclerosis-100533606","NCT06228001","Holter of Movement in Patients With Amyotrophic Lateral Sclerosis.","ActiALS",{"count":298,"type":20},"5 Years","ActiALS is a multicentric academic study. Patients with amyotrophic lateral sclerosis (ALS) may be included on a voluntary basis. The investigators plan to include a group of approximately 30 patients with ALS.\n\nThe investigators have planned to assess patient every three months for a year. After each visit, participants will wear Actimyo for one month daily.",[212],[214,168,169],{"date":324,"type":35},"2025-05-19",{"date":326,"type":35},"2023-05-01",{"date":310,"type":20},{"name":41,"class":42},3,{"id":331,"slug":332,"hasResults":11,"nctId":333,"briefTitle":334,"officialTitle":335,"acronym":4,"eligibilityCriteria":336,"healthyVolunteers":51,"sex":52,"minAge":337,"maxAge":338,"enrollmentInfo":339,"targetDuration":4,"studyType":21,"phases":340,"briefSummary":341,"conditions":342,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":348,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":354},"100514716","assessments-in-patients-with-muscular-pathology-and-in-control-subjects--the-actilige-next-study-100514716","NCT05982119","Assessments in Patients With Muscular Pathology and in Control Subjects : The ActiLiège Next Study","Gait Analysis Parameter, Stair Climbing and Upper Limb Evaluation in Patients With Muscular Pathology and in Control Subjects: The ActiLiège Next Study","Inclusion criteria\n\n* For the patients:\n\n  * Genetically confirmed diagnosis of DMD, FSHD, DM1, CMT or FKRP mutations or confirmed CNM based on muscle biopsy.\n  * FSHD, DM1, CMT and CNM patients should be ambulant or in transition.\n  * DM1 and CMT patients should present sensori-motor signs on physical examination.\n  * Under the age of 20 years for patients with DMD, CNM or between the ages of 5 and 80 years for patients with FSHD, CMT and DM1.\n  * More than 2 years old for patients with FKRP mutations\n  * Non-ambulant DMD patients must be able to remain seated in an arm- or a wheelchair for at least one hour.\n  * Patients with DMD treated with corticosteroids for at least 6 months or initiated corticosteroid at V0 (except for patients under 4).\n  * Signed informed consent form by patient himself or, in case of minor patients, signed informed consent form by patient's parents or legal guardians.\n* For the control subjects:\n\n  * Ambulant boys and girls under 20 years old\n  * Signed informed consent form by patient him\u002Fherself or, in case of minor patients, signed informed consent form by patient's parents or legal guardians.\n\nExclusion Criteria:\n\n* For the patients:\n\n  * Patients with extreme cognitive disorders that limit their understanding of the exercises to be performed.\n  * Patients who have undergone a surgical procedure or who have experienced recent trauma (within fewer than 6 months) affecting the upper or lower limbs (for ambulant patients).\n  * A concomitant chronic or acute neurological, endocrine, infectious, allergic, or inflammatory pathology within the 3-week period immediately prior to inclusion.\n  * Patients who are participating in an interventional clinical trial.\n  * DMD patients in transition who are not on corticosteroids.\n* For the control subjects:\n\n  * Patients who have undergone a surgical procedure or who have experienced recent trauma (within fewer than 6 months) affecting the upper or lower limbs.\n  * Elite athletes (at the national level).\n  * A chronic or acute muscular, neurological, infectious, or inflammatory pathology within the 3-week period immediately prior to inclusion.\n  * An orthopedic, neuromuscular, or neurological pathology that affects the quality of the subject's walking gait.","1 Year","80 Years",{"count":265,"type":20},[23],"The objective of the ActiLiège Next study is to collect longitudinal data from patients and control subjects using a wearable magneto-inertial device. By collecting natural history data in various neuromuscular disorders (Duchenne Muscular Dystrophy, Fascioscapulohumeral Muscular Dystrophy, Myotonic Dystrophy 1, Charcot-Marie-Tooth, Centronuclear Myopathy, Congenital Muscular Dystrophy), we aim to validate digital outcome measures to continuously assess motor function in real-life.",[343,344,271,345,346,347],"Duchenne Muscular Dystrophy","Fascioscapulohumeral Muscular Dystrophy","Charcot-Marie-Tooth","Centronuclear Myopathy","Congenital Muscular Dystrophy",{"date":306,"type":35},{"date":350,"type":35},"2020-07-10",{"date":352,"type":20},"2026-03",{"name":41,"class":42},8,{"id":356,"slug":357,"hasResults":11,"nctId":358,"briefTitle":359,"officialTitle":360,"acronym":4,"eligibilityCriteria":361,"healthyVolunteers":11,"sex":52,"minAge":53,"maxAge":4,"enrollmentInfo":362,"targetDuration":4,"studyType":21,"phases":363,"briefSummary":364,"conditions":365,"keywords":367,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":374,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":380,"locationsCount":43},"100586553","optimizing-care-for-diabetic-patients-in-hospitalized-rehabilitation-through-structured-education-100586553","NCT06916871","Optimizing Care for Diabetic Patients in Hospitalized Rehabilitation Through Structured Education","Optimizing Care for Diabetic Patients in Hospitalized Rehabilitation Through Structured Education.","Inclusion Criteria:\n\n* Patient having given written consent.\n* Diagnosis of diabetes notified in medical file.\n* Be at least 18 years old.\n* Be able to communicate orally and in writing.\n* Have a sufficient understanding of the French language.\n\nExclusion Criteria:\n\n* Presence of cognitive disorder, confusion, spatio-temporal disorientation noted in the nursing and\u002For medical file.",{"count":134,"type":20},[23],"A large number of patients at the Neurological and Functional Rehabilitation Centre of the University Hospital of Liège have associated pathologies, including diabetes. These patients may have diabetes-related complications that require recurrent hospitalizations in an acute structure or in rehabilitation. One of the ways to limit complications is to set up patient education.\n\n1. Objectives\n\n   * To compare the impact of management through formal education with that of awareness.\n   * To evaluate the impact on knowledge of structured education.\n   * To evaluate the impact of structured education on the quality of life experienced by diabetic patients.\n   * Identify the patient's level of satisfaction with the education sessions.\n   * To evaluate the impact of structured education on the biological improvement of glycated hemoglobin.\n   * To evaluate the impact of structured education on diabetes-related complications.\n2. Working Hypothesis The implementation of structured diabetes education allows \"patients to acquire, or maintain, the skills they need to manage their lives as well as possible despite the constraints of chronic disease... \".\n3. Study population All diabetic patients hospitalized in all care units.\n4. Collection tools and techniques Collection tools\n\n1\\. \"Diabetes Knowledge Questionnaire\". 2. SF-36 Health Questionnaire. 3. Satisfaction questionnaire for structured sessions on diabetes. 4. Questionnaire to identify complications and\u002For re-hospitalizations after your stay in rehabilitation.\n\nCollection technology At admission (D+1)\n\n* Validation of inclusion and exclusion criteria.\n* Submission and distribution of the information and consent form.\n* Obtaining informed consent from the patient.\n* Distribution of collection tools 1 and 2 (collection on D+2).\n* Control of glycated hemoglobin. At the end of hospitalization (D-2)\n* Distribution of collection tools 1, 2 and 3 on D-2 before the release (collection on D-1).\n* Control of glycated hemoglobin. 3 months after the end of hospitalization\n* Sending collection tools 1, 2 and 4 by post. The patient will be invited to complete them and return them by post.\n* The patient will be invited to take a blood test for glycated hemoglobin.",[366],"Diabetes Mellitus Self Management Education",[368,369,370,371,372],"optimisation","autonomie","diabète","réadaptation","éducation","2025-04-01",{"date":375,"type":35},"2025-04-08",{"date":377,"type":20},"2025-04-07",{"date":379,"type":20},"2027-10-31",{"name":41,"class":42},{"id":382,"slug":383,"hasResults":11,"nctId":384,"briefTitle":385,"officialTitle":386,"acronym":387,"eligibilityCriteria":388,"healthyVolunteers":11,"sex":389,"minAge":53,"maxAge":390,"enrollmentInfo":391,"targetDuration":4,"studyType":21,"phases":393,"briefSummary":395,"conditions":396,"keywords":399,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":402,"lastUpdatePostDateStruct":403,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":409,"locationsCount":43},"100474631","phase-3-treatment-preventive-for-pre-eclampsia-by-acetylsalicylic-acid-in-women-who-underwent-frozen-embryo-transfer-100474631","NCT05460416","Treatment Preventive for Pre-eclampsia by Acetylsalicylic Acid in Women Who Underwent Frozen Embryo Transfer","A Prospective Interventional Randomized Controlled Trial to Assess the Effect of Low Dose Acetylsalicylic Acid As a Preventive Treatment of Pre-eclampsia in Pregnant Women Who Underwent Frozen Embryo Transfer","TePPAFET","Inclusion Criteria:\n\n* Healthy women from \\[18 - 43\\] years-old, planned for a frozen embryo transfer, with natural and modified natural or HRT cycle\n* Who have given their informed consent\n* Who have a confirmed pregnancy at week 6 of amenorrhea.\n\nExclusion Criteria:\n\n* Women presenting one risk factor for preeclampsia: multiple pregnancy, history of preeclampsia, BMI \\> 30, lupus syndrome, preexistent proteinuria, non-treated chronic high blood pressure (\\>140\u002F90), antiphospholipid antibody syndrome, diabetes (fasting blood sugar \\>126mg\u002Fdl)\n* Contraindication to acetylsalicylic acid (at risk of active hemorrhage (like hemophilia, …); at risk of or who have a gastro-duodenal ulcer; at risk or how have a terminal renal or hepatic in-sufficiency (only if acetylsalicylic acid is given at high dose)\n* Already treated with acetylsalicylic acid\n* Treatment with anticoagulants or non-steroid anti-inflammatory drugs","FEMALE","43 Years",{"count":392,"type":20},276,[394],"PHASE3","Title: A prospective multicentric interventional randomized controlled trial to assess the effect of low dose acetylsalicylic acid as a preventive treatment of pre-eclampsia in pregnant women who underwent frozen embryo transfer",[397,398],"Embryo Transfer","Hypertension, Pregnancy Induced",[400,401],"embryo transfer","Hypertension, Pregnancy induced","2025-02-14",{"date":404,"type":35},"2025-02-18",{"date":406,"type":35},"2022-10-25",{"date":408,"type":20},"2026-06-30",{"name":41,"class":42},{"id":411,"slug":412,"hasResults":11,"nctId":413,"briefTitle":414,"officialTitle":415,"acronym":416,"eligibilityCriteria":417,"healthyVolunteers":11,"sex":52,"minAge":53,"maxAge":418,"enrollmentInfo":419,"targetDuration":4,"studyType":188,"phases":4,"briefSummary":421,"conditions":422,"keywords":424,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":426,"startDateStruct":428,"completionDateStruct":430,"leadSponsor":431,"locationsCount":43},"100530197","exploratory-study-on-predicting-cidp-patients-decline-during-iv-immunoglobulin-treatment-adaptation-feasibility-100530197","NCT06183645","Exploratory Study on Predicting CIDP Patients' Decline During IV Immunoglobulin Treatment Adaptation Feasibility.","ActiCIDP : Exploratory Study on the Feasibility of Predicting CIDP Patients' Evolution Decline During Intravenous Immunoglobulins Treatment Adaptation.","ActiCIDP","Inclusion Criteria:\n\n* Diagnosed with CIDP or possible CIDP based on 2021 EAN\u002FPNS criteria2.\n* Treated with IVIg (≤1g\u002Fkg\u002F3-8week)\n* Clinically Stable disease for 3 months (according to treating physician opinion).\n* No treatment withdrawal failure within 1 year\n* Age over 18 years\n\nExclusion Criteria:\n\n* Significant cognitive or communication disorders\n* Surgery or serious traumatic injury ≤ 6 months\n* Non ambulant patient\n* Current participation to a therapeutic trial\n* Anti-myeline antibodies (anti-MAG) positive or nodo-paranodopathy\n* Other autoimmune disease that requires Corticosteroids, IVIg, Plasma Exchange treatment\n* Pregnancy or breastfeeding\n* Any other condition that, according to the investigator, could significantly interfere with patient evaluation or safety.","99 Years",{"count":420,"type":20},40,"ActiCIDP is a monocentric academic study. Patients with Chronic inflammatory demyelinating polyradiculoneuritis may be included on a voluntary basis.\n\nThe investigators plan to include a group of approximately 40 patients with CIDP.\n\nThe investigators have planned to assess patient every three months for a year. After each visit, participants will wear Actimyo for one month daily.",[423],"Chronic Inflammatory Demyelinating Polyneuropathy",[214,168,169],"2025-02-10",{"date":427,"type":35},"2025-02-12",{"date":429,"type":35},"2023-08-28",{"date":310,"type":20},{"name":41,"class":42},{"id":433,"slug":434,"hasResults":11,"nctId":435,"briefTitle":436,"officialTitle":437,"acronym":438,"eligibilityCriteria":439,"healthyVolunteers":51,"sex":389,"minAge":53,"maxAge":230,"enrollmentInfo":440,"targetDuration":442,"studyType":188,"phases":4,"briefSummary":443,"conditions":444,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":453,"lastUpdatePostDateStruct":454,"startDateStruct":456,"completionDateStruct":458,"leadSponsor":460,"locationsCount":329},"100564215","fertility-and-ovarian-reserve-in-female-childhood-cancer-survivors-100564215","NCT06626282","Fertility and Ovarian Reserve in Female Childhood Cancer Survivors","PReserving Fertility and Quality of Life IN Belgian Female Paediatric CancEr SurvivorS","PRINCESS","Inclusion Criteria:\n\n* Child and adolescent female patients included in the Paediatrics Late Effects Project:\n* diagnosed with cancer1 between 01\u002F01\u002F2004 and 31\u002F12\u002F2018\n* \\\u003C17 years old at diagnosis\n* treated at CHU Liège site Citadelle or CHC, Cliniques Universitaires Saint-Luc and HUDERF\n* alive\n* ≥ 18 years-old at time of recruitment.\n\nExclusion Criteria:\n\n* Cancer diagnosis for controls",{"count":441,"type":20},340,"3 Months","Ovarian function impairment affects the quality of life of the survivors of paediatric cancer by impacting fertility, bone quality and mental and cognitive health. The objective of this project is to evaluate the impact of low-intermediate dose alkylating agents associated or not with ovarian cryopreservation technique on ovarian function in female survivors of paediatric cancer. We propose to identify new epigenetic markers in order to predict the risk of premature ovarian insufficiency. The project will be led by a national multi-disciplinary team (paediatric oncologists, gynaecologists, endocrinologists). Paediatric cancer clinical data (therapy, fertility preservation, ...) will be extracted from the Paediatrics Late Effects database and additional data will be collected during PRINCESS fertility evaluation. Through translational and multi-disciplinary approaches, results should improve quality of life and fertility preservation in female survivors of paediatric cancer by developing new personalised screening tools for premature ovarian insufficiency.",[445,446,447,448,449,450,451,452],"Childhood Cancer Survivors","Fertility","Ovarian Reserve","CED","Ovarian Reserve Markers","Cryopreservation","Alkylating Agents","Female","2024-10-30",{"date":455,"type":35},"2024-11-01",{"date":457,"type":35},"2024-10-09",{"date":459,"type":20},"2028-12-31",{"name":41,"class":42},{"id":462,"slug":463,"hasResults":11,"nctId":464,"briefTitle":465,"officialTitle":465,"acronym":4,"eligibilityCriteria":466,"healthyVolunteers":51,"sex":52,"minAge":53,"maxAge":4,"enrollmentInfo":467,"targetDuration":4,"studyType":21,"phases":468,"briefSummary":469,"conditions":470,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":472,"lastUpdatePostDateStruct":473,"startDateStruct":475,"completionDateStruct":477,"leadSponsor":479,"locationsCount":43},"100501113","peri-implant-soft-tissue-integration-in-humans-influence-of-material-100501113","NCT05805033","Peri-Implant Soft Tissue Integration in Humans: Influence of Material","Inclusion Criteria:\n\n* Participants have to voluntarily sign the informed consent form before any study related action\n* Patients aged 18 or over\n* Patients with one or more missing teeth in the maxillary or mandible area, seeking implant therapy\n* Men\u002Fwomen\n* Patients in good systemic health (ASA I\u002F II) and no contraindication for oral surgical interventions\n* Patients requiring a replacement of missing teeth; the tooth at the implant site(s) must have been extracted or lost at least 12 weeks before the date of implantation\n* At least 3 mm of fibrous mucosa in the bucco-lingual dimension\n* Full mouth plaque score (FMPI) lower than or equal to 25%\n* At least a diameter of 4 mm for the implant (regular diameter)\n\nExclusion Criteria:\n\n* Autoimmune disease requiring medical treatment\n* Medical conditions requiring prolonged use of steroids\n* Use of Bisphosphonates intravenously or more than 3 years of oral use\n* Infection (local or systemic) - patients with gingivitis or active local infection will undergo a medical treatment prior to the entrance to the study, and each individual will be evaluated for suitability; in case of a systemic infection, the evaluation will be based on medical anamneses, and if necessary, a patient will be referred to relevant medical tests\n* Current pregnancy or breastfeeding women\n* Alcoholism or chronical drug abuse\n* Immunocompromised patients\n* Uncontrolled diabetes\n* Smokers\n* Prisoners\n* Implant's diameter under 4 mm (narrow implant)\n* Conditions or circumstances, in the opinion of the investigator, which would prevent completion of the study or interference with analysis of study results, such as history of non-compliance, or unreliability",{"count":420,"type":20},[23],"The purpose of this study is to compare the mucointegration of 2 types of surface roughness of zirconia abutments with titanium. The surface roughness will be machined and ultra-polished.",[471],"Healthy Subjects","2024-09-01",{"date":474,"type":35},"2024-09-05",{"date":476,"type":35},"2023-09-22",{"date":478,"type":20},"2024-10-01",{"name":41,"class":42},{"id":481,"slug":482,"hasResults":11,"nctId":483,"briefTitle":484,"officialTitle":485,"acronym":4,"eligibilityCriteria":486,"healthyVolunteers":51,"sex":52,"minAge":53,"maxAge":4,"enrollmentInfo":487,"targetDuration":4,"studyType":21,"phases":489,"briefSummary":490,"conditions":491,"keywords":493,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":495,"lastUpdatePostDateStruct":496,"startDateStruct":498,"completionDateStruct":500,"leadSponsor":502,"locationsCount":43},"100559927","comparison-of-conventional-impressions-intraoral-scanners-and-digital-photogrammetry-for-full-arch-implant-prosthesis-100559927","NCT06570499","Comparison of Conventional Impressions, Intraoral Scanners and Digital Photogrammetry for Full-arch Implant Prosthesis.","Precision, Patient Satisfaction and Timing of Complete-arch Digital Implant Impression With a Conventional Impression, an Intraoral Scanner and a Photogrammetry Technique: A Prospective Clinical Comparative Study","Inclusion Criteria:\n\n* edentulous maxilla or mandible with 4 to 8 osseointegrated implants (NobelBiocare®) and transgingival abutments tightened to 35N\u002Fcm (Multi-unit, NobelBiocare®).\n\nExclusion Criteria:\n\n* Patients with non-osseointegrated implants\n* Patients with different implant systems\n* Patients with incomplete edentulism",{"count":488,"type":20},20,[23],"The aim of this clinical trial is to compare implant-supported definitive impressions in edentulous patients (mandible or maxilla) with 4 to 8 osseointegrated implants. The main questions it aims to answer are :\n\nThe primary outcome of this prospective clinical comparative study is to analyse the precision of a complete-arch impression.\n\nThe secondary aim is to obtain patient satisfaction with these new types of impression.\n\nThe different impressions (conventional, intraoral scanner and photogrammetry) will be taken twice on the same patient.",[492],"Dental Implant Failed",[494],"accuracy, photogrammetry, dental implant","2024-08-23",{"date":497,"type":35},"2024-08-26",{"date":499,"type":35},"2024-06-18",{"date":501,"type":20},"2024-12-15",{"name":41,"class":42},""]